Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Salloway, Stephen; A. Sperling, Reisa; C. Fox, Nick; Blennow, Kaj; E. Klunk, William; A. Raskind, Murray; N. Sabbagh, Marwan; S. Honig, Lawrence; P. Porsteinsson, Anton; H. Ferris, Steven; Reichert, Marcel; Ketter, Nzeera; Nejadnik, Bijan; Guenzler, Volkmar; Miloslavsky, Maja; Wang, Daniel; Lü, Yuan; Lull, Julia; Cristina Tudor, Iulia; Liu, Enchi; Grundman, Michael; Yuen, Eric; S. Black, Ronald; Robert Brashear, H.

doi:10.1056/nejmoa1304839

Public

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Published in New England Journal of Medicine • Jan 22, 2014

Authors:

Stephen Salloway

Reisa A. Sperling

Nick C. Fox

Abstract

BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one i...

Subject

Medicine

Placebo

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!